KORU Medical Systems, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by KORU Medical Systems, Inc. (KRMD) on June 24, 2026. The filing discloses the entry into a Material Definitive Agreement involving an amendment to a key manufacturing contract.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity figures. This report focuses exclusively on contractual terms rather than financial performance data.
Material Changes
On June 24, 2026, the Company entered into Amendment No. 1 to its Amended and Restated Manufacturing and Supply Agreement with Command Medical Products, LLC. Key changes include:
- Term Extension: The initial term is extended to December 31, 2031, with automatic one-year renewals unless terminated with 180 days' notice.
- Pricing and Payment: Modifications to product pricing, annual price adjustments, and the application of pass-through cost savings.
- Second Manufacturing Site: Command is obligated to obtain and qualify a second manufacturing site by December 31, 2027. Failure to do so (subject to a 30-day cure period) grants KORU the right to terminate.
- Exclusivity: Command is established as the exclusive manufacturer for a limited set of products.
- Intellectual Property: Clarification of IP ownership and licenses between the parties.
- Non-Competition: The non-competition provision has been removed.
Outlook, Risks, and Management Commentary
The amendment introduces a specific termination risk if Command fails to qualify the second manufacturing site by the December 31, 2027 deadline. Standard termination rights remain in place for material breach (uncured within 45 days), bankruptcy, insolvency, or force majeure lasting 30 days. The filing does not contain forward-looking financial guidance or management commentary beyond the description of the agreement's terms.
Investor Verification Checklist
- Verify the specific pricing adjustments and pass-through cost savings mechanisms detailed in Exhibit 10.1.
- Monitor Command Medical Products, LLC's progress toward qualifying the second manufacturing site by the December 31, 2027 deadline.
- Review the scope of the "limited set of Products" designated for exclusive manufacturing by Command.
- Assess the impact of removing the non-competition provision on the Company's competitive landscape.